Survodutide

Research Phase

Survodutide (BI 456906)

Aliases
BI 456906
Administration
Subcutaneous injection

Documented benefits

Tier 1 · Peer-reviewed / regulatory

Benefit categories

Weight Loss & Metabolism

Survodutide's defining research application — combining GLP-1's appetite suppression with glucagon's calorie-burning effect in one compound.

Weight loss

Phase 2 trial data showed substantial weight loss, with the added energy-expenditure effect distinguishing its results from GLP-1-only compounds.

Increased energy expenditure

Its core, defining point of difference — the glucagon receptor activation directly raises resting calorie burn, an effect semaglutide and tirzepatide's GIP pathway don't replicate.

Appetite suppression

Suppresses appetite through the same GLP-1 receptor pathway used by semaglutide and tirzepatide.